Exploiting the curative potential of adoptive T‐cell therapy for cancer

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Coordinated regulation of myeloid cells by tumours

Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities

Mog, B. J., Marcou, N., DiNapoli, S. R., Pearlman, A. H., Nichakawade, T. D., Hwang, M. S., Douglass, J., Hsiue, E. H.-C., Glavaris, S. A., Wright, K. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7123 · Cited by 31

Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy

Hinrichs, C. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1294 · Cited by 30

Immunotherapy in colorectal cancer

Agarwal, P., Le, D. T., & Boland, P. M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.03.002 · Cited by 31

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

Green, D. S., Nunes, A. T., David‐Ocampo, V., Ekwede, I., Houston, N. D., Highfill, S. L., Khuu, H. M., Stroncek, D. F., Steinberg, S. M., Zoon, K. C., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1569-5 · Cited by 30

Engineered human pluripotent stem cell-derived natural killer cells with PD-L1 responsive immunological memory for enhanced immunotherapeutic efficacy

Chang, Y., Jin, G., Luo, W., Luo, Q., Jung, J., Hummel, S. N., Torregrosa‐Allen, S. E., Elzey, B. D., Low, P. S., Lian, X. L., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.03.018 · Cited by 30

Towards Neuroimmunotherapy for Cancer: the Neurotransmitters Glutamate, Dopamine and GnRH-II augment substantially the ability of T cells of few Head and Neck cancer patients to perform spontaneous migration, chemotactic migration and migration towards the autologous tumor, and also elevate markedly the expression of CD3zeta and CD3epsilon TCR-associated chains

Saussez, S., Laumbacher, B., Chantrain, G., Rodriguez, A., Gu, S., Wank, R., & Levite, M. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1242-y · Cited by 30

The biology and therapeutic management of melanoma brain metastases

Abate‐Daga, D., Ramello, M. C., Smalley, I., Forsyth, P. A., & Smalley, K. S. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.019 · Cited by 30

T cell engineering as therapy for cancer and HIV: our synthetic future

June, C. H., & Levine, B. L. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0374 · Cited by 31

Biomaterial-Based Activation and Expansion of Tumor-Specific T Cells

Schluck, M., Hammink, R., Figdor, C. G., Verdoes, M., & Weiden, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00931 · Cited by 30

Semiflexible Immunobrushes Induce Enhanced T Cell Activation and Expansion

Hammink, R., Weiden, J., Voerman, D., Popelier, C., Eggermont, L. J., Schluck, M., Figdor, C. G., & Verdoes, M. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c21994 · Cited by 29

Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells

Nielsen, J. S., Sedgwick, C. G., Shahid, A., Zong, Z., Brumme, Z. L., Yu, S., Liu, L. Y., Kroeger, D. R., Treon, S. P., Connors, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2023 · Cited by 29

Cellular Immunotherapy of Canine Cancer

Addissie, S., & Klingemann, H. (2018) · Veterinary Sciences · doi:10.3390/vetsci5040100 · Cited by 28

Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion

Gan, L.-L., Hii, L., Wong, S. F., Leong, C., & Mai, C. (2020) · Cancers · doi:10.3390/cancers12071872 · Cited by 28

Characteristics of CD8+ and CD4+ Tissue-Resident Memory Lymphocytes in the Gastrointestinal Tract

Li, P., Zhang, Y., Xu, Y., Cao, H., & Li, L. (2022) · Advanced Gut & Microbiome Research · doi:10.1155/2022/9157455 · Cited by 28

Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment

Camisaschi, C., Vallacchi, V., Castelli, C., Rivoltini, L., & Rodolfo, M. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.928206 · Cited by 28

CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade

Zheng, A., Du, Y., Wang, Y., Zheng, Y., Ning, Z., Wu, M., Zhang, C., Zhang, D., Liu, J., & Liu, X. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.010 · Cited by 27

Injectable Diels–Alder cycloaddition hydrogels with tuneable gelation, stiffness and degradation for the sustained release of T-lymphocytes

Yan, J., Gundsambuu, B., Krasowska, M., Platts, K., Marina, P. F., Gerber, C., Barry, S. C., & Blencowe, A. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00274d · Cited by 29

Cytosolic Delivery of Liposomal Vaccines by Means of the Concomitant Photosensitization of Phagosomes

Hjálmsdóttir, Á., Bühler, C., Vonwil, V., Roveri, M., Håkerud, M., Waeckerle‐Men, Y., Gander, B. A., & Johansen, P. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00394 · Cited by 27

Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours

Durgeau, A., Virk, Y., Gros, G., Voilin, E., Corgnac, S., Djenidi, F., Salmon, J., Adam, J., de Montpréville, V., Validire, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07603-1 · Cited by 28

Tumor-infiltrating immune repertoires captured by single-cell barcoding in emulsionPreprint

Briggs, A. W., Goldfless, S. J., Timberlake, S. C., Belmont, B. J., Clouser, C. R., Koppstein, D., Sok, D., Heiden, J. V., Tamminen, M. V., Kleinstein, S. H., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/134841 · Cited by 27

Advances in adoptive T-cell therapy for metastatic melanoma

Das, A., Ghose, A., Naicker, K., Sanchez, E., Chargari, C., Rassy, E., & Boussios, S. (2023) · Current Research in Translational Medicine · doi:10.1016/j.retram.2023.103404 · Cited by 26

Nanotechnologies for enhancing cancer immunotherapy

Yang, J., Wang, C., Shi, S., & Dong, C. (2020) · Nano Research · doi:10.1007/s12274-020-2904-8 · Cited by 26

Immunotherapy: Current Status and Future Perspectives

Floudas, C. S., Brar, G. S., & Greten, T. F. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05516-7 · Cited by 25

Antitumor Activities of Interleukin-12 in Melanoma

Gao, W., Pan, J., & Pan, J. (2022) · Cancers · doi:10.3390/cancers14225592 · Cited by 25

The combination of NK and CD8+ T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells

Ye, J., Qi, W.-X., Liu, M., & Li, Y. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.06.002 · Cited by 25

Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers

Bradley, S. D., Talukder, A. H., Lai, I. P., Davis, R. K., Alvarez, H., Tiriac, H., Zhang, M., Chiu, Y., Melendez, B., Jackson, K. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19141-w · Cited by 29

Pan-cancer analysis of neoepitopes

Teku, G., & Vihinen, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-30724-y · Cited by 24

Direct In Vivo Activation of T Cells with Nanosized Immunofilaments Inhibits Tumor Growth and Metastasis

Weiss, L., Weiden, J., Dölen, Y., Grad, E. M., van Dinther, E. A. W., Schluck, M., Eggermont, L. J., van Mierlo, G., Gileadi, U., Bartoló‐Ibars, A., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c11884 · Cited by 24

Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology

Yoo, H. J., & Harapan, B. N. (2021) · Immunologic Research · doi:10.1007/s12026-021-09236-x · Cited by 25

Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer

Ferrer, G., Álvarez‐Errico, D., & Esteller, M. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac088 · Cited by 23

The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress

Javid, H., Attarian, F., Saadatmand, T., Rezagholinejad, N., Mehri, A., Amiri, H., & Karimi‐Shahri, M. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30402 · Cited by 23

Syngeneic Syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting

Siurala, M., Vähä-Koskela, M. J. V., Havunen, R., Tähtinen, S., Bramante, S., Parviainen, S., Mathis, J. M., Kanerva, A., & Hemminki, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1136046 · Cited by 24

Aging promotes acquisition of naive-like CD8+ memory T cell traits and enhanced functionalities

Eberlein, J., Davenport, B., Nguyen, T. T., Victorino, F., Haist, K. C., Jhun, K., Karimpour‐Fard, A., Hunter, L., Kedl, R. M., Clambey, E. T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88546 · Cited by 23

Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs

Brockman, M. A., Jones, R. B., & Brumme, Z. L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00506 · Cited by 22

Expansion of Tumor-Infiltrating Lymphocytes from Melanoma Tumors

Wickström, S. L., & Lövgren, T. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-8979-9_7 · Cited by 22

Immunomodulatory Function of Interleukin-15 and Its Role in Exercise, Immunotherapy, and Cancer Outcomes

Farley, M. J., Bartlett, D. B., Skinner, T. L., Schaumberg, M. A., & Jenkins, D. G. (2022) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003067 · Cited by 24

Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model

Mony, J. T., Zhang, L., Ma, T., Grabosch, S., Tirodkar, T. S., Brozick, J., Tseng, G. C., Elishaev, E., Edwards, R. P., Huang, X., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1712-6 · Cited by 22

Advances in the Pharmacological Activities and Effects of Perilla Ketone and Isoegomaketone

Wang, R., Zhang, Q., Feng, C., Zhang, J., Qin, Y., & Meng, L. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8809792 · Cited by 22

Leveraging biomaterials for enhancing T cell immunotherapy

Liao, Z., Zhang, W., Zheng, H., Wang, Y., Yu, J., Li, H., & Gu, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.023 · Cited by 22

Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside

Bhome, R., AlSaihati, H., Goh, R. W., Bullock, M. D., Primrose, J. M., Thomas, G. J., Sayan, E., & Mirnezami, A. H. (2016) · European Journal of Molecular & Clinical Medicine · doi:10.1016/j.nhtm.2016.03.001 · Cited by 22

Modulation of T cell function and survival by the tumor microenvironment

Mani, N. L., Andrews, D., & Obeng, R. C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1191774 · Cited by 22

Marrow-Infiltrating Lymphocytes – Role in Biology and Cancer Therapy

Borrello, I., & Noonan, K. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00112 · Cited by 21

Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens

Miller, A. M., Bahmanof, M., Zehn, D., Cohen, E. E. W., & Schoenberger, S. P. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0371 · Cited by 21

Mechanisms of resistance to T cell‐based immunotherapy in head and neck cancer

Lee, M. Y., & Allen, C. T. (2020) · Head & Neck · doi:10.1002/hed.26158 · Cited by 21

Novel Targets in Pancreatic Cancer Research

Kozak, G. M., Blanco, F. F., & Brody, J. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.12.015 · Cited by 20

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy

Wan, Y., Simovic, B., & Walsh, S. R. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s66079 · Cited by 20

Vaccination With Trifunctional Nanoparticles That Address CD8 + Dendritic Cells Inhibits Growth of Established Melanoma

Shen, L., Krauthäuser, S., Fischer, K., Hobernik, D., Abassi, Y., Dzionek, A., Nikolaev, A., Voltz, N., Diken, M., Krummen, M., et al. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0174 · Cited by 20

Targeted Cell-to-Cell Delivery of Protein Payloads via the Granzyme-Perforin Pathway

Woodsworth, D. J., Dreolini, L., Abraham, L., & Holt, R. A. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.10.003 · Cited by 22

Iodine-124 Based Dual Positron Emission Tomography and Fluorescent Labeling Reagents for In Vivo Cell Tracking

Pham, T., Lu, Z., Davis, C. G., Li, C., Sun, F., Maher, J. F., & Yan, R. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00799 · Cited by 20

Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer

Huang, M., Liu, L., Zhu, J., Jin, T., Chen, Y., Xu, L., Cheng, W., Ruan, X., Su, L., Meng, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.723817 · Cited by 20

Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy

Sharma, R., Chheda, Z. S., Jala, V. R., & Haribabu, B. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.982101 · Cited by 20

Adoptive T-cell therapy for Leukemia

Garber, H. R., Mirza, A., Mittendorf, E. A., & Alatrash, G. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-25 · Cited by 21

Identification of Small Novel Coding Sequences, a Proteogenomics Endeavor

Olexiouk, V., & Menschaert, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-42316-6_4 · Cited by 19

Divergent Peptide Presentations of HLA-A*30 Alleles Revealed by Structures With Pathogen Peptides

Zhu, S., Liu, K., Chai, Y., Wu, Y., Lü, D., Xiao, W., Cheng, H., Zhao, Y., Ding, C., Lyu, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01709 · Cited by 20

Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of αMSH peptide

Yang, H., Gao, F., McNeil, B. L., Zhang, C., Yuan, Z., Zeisler, S., Kumlin, J. O., Zeisler, J., Bénard, F., Ramogida, C. F., et al. (2021) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-020-00119-4 · Cited by 19

Xenogene vaccination in the therapy of cancer

Cavallo, F., Aurisicchio, L., Mancini, R., & Ciliberto, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.927433 · Cited by 19

Genotyping of cutaneous melanoma.

Glitza, I. C., & Davies, M. A. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.03.01 · Cited by 18

Ectopic expression of anti-HIV-1 shRNAs protects CD8+ T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation

Kamata, M., Kim, P. Y., Ng, H. L., Ringpis, G.-E. E., Kranz, E. O., Chan, J., O'Connor, S., Yang, O. O., & Chen, I. S. Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.026 · Cited by 18

Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics

Mooradian, M. J., & Sullivan, R. J. (2017) · Future Oncology · doi:10.2217/fon-2017-0117 · Cited by 18

Classifying the Linkage between Adipose Tissue Inflammation and Tumor Growth through Cancer-Associated Adipocytes.

Song, Y. C., Lee, S. E., Jin, Y., Park, H. W., Chun, K., & Lee, H. (2020) · PubMed · doi:10.14348/molcells.2020.0118 · Cited by 19

Adoptive CD8 + T-cell grafted with liposomal immunotherapy drugs to counteract the immune suppressive tumor microenvironment and enhance therapy for melanoma

Liu, S., Liu, H., Song, X., Jiang, A., Deng, Y., Yang, C., Sun, D., Jiang, K., Yang, F., & Zheng, Y. (2021) · Nanoscale · doi:10.1039/d1nr04036g · Cited by 18

Immunotherapy for the treatment of breast cancer

Ayala, M. A. M., Gottardo, M. F., Asad, A. S., Zuccato, C. F., Candia, A. J. N., Seilicovich, A., & Candolfi, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1324566 · Cited by 20

Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review

Naik, P. P. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00583-z · Cited by 17

Neoadjuvant personalized cancer vaccines: the final frontier?

Richard, G., Ruggiero, N., Steinberg, G. D., Martin, W. D., & Groot, A. S. D. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2303015 · Cited by 17

Adoptive T Cell Therapy Targeting CD1 and MR1

Guo, T., Chamoto, K., & Hirano, N. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00247 · Cited by 17

2015 Guidance on cancer immunotherapy development in early‐phase clinical studies

Working Group for Effector Cell Therapy, Working Group for Cancer Vaccines and Adjuvants, & Working Group for Anti‐immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy (2015) · Cancer Science · doi:10.1111/cas.12819 · Cited by 17

Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy

Brar, G. S., Greten, T. F., & Brown, Z. J. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818808086 · Cited by 17

Immunotherapy in Anal Cancer

Phuong, L., & Rajdev, L. N. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00946-3 · Cited by 17

Identification of NY-ESO-1157–165 Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy

Zhang, H., Sun, M., Wang, J., Zeng, B., Cao, X., Han, Y., Tan, S., & Gao, G. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.644520 · Cited by 17

The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community

Koşaloğlu‐Yalçın, Z., Blazeska, N., Carter, H. K., Nielsen, M., Cohen, E. E. W., Kufe, D. W., Conejo-Garcia, J. R., Robbins, P. F., Schoenberger, S. P., Peters, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.735609 · Cited by 18

Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells

Pato, A., Eisenberg, G., Machlenkin, A., Margalit, A., Cafri, G., Frankenburg, S., Merims, S., Peretz, T., Lotem, M., & Gross, G. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12688 · Cited by 17

FDA Experience on CAR T Cell Pharmacokinetics/Pharmacodynamics and Model‐Based Assessments

Tegenge, M. A., Wang, X., Liu, J., Zhu, H., & Fashoyin‐Aje, L. A. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3703 · Cited by 16

William B. Coley

Loughlin, K. R. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.07.001 · Cited by 16

Immunotherapy of Cancer

Sharma, A., Campbell, M. T., Yee, C., Goswami, S., & Sharma, P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-7020-6896-6.00077-6 · Cited by 17

Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties

Balasiddaiah, A., Davanian, H., Aleman, S., Pasetto, A., Frelin, L., Sällberg, M., Lohmann, V., Koh, S., Bertoletti, A., & Chen, M. (2017) · Journal of Virology · doi:10.1128/jvi.00010-17 · Cited by 16

Cancer Immunology and CAR-T Cells: A Turning Point Therapeutic Approach in Colorectal Carcinoma with Clinical Insight

Ray, S. K., Meshram, Y., & Mukherjee, S. (2020) · Current Molecular Medicine · doi:10.2174/1566524020666200824103749 · Cited by 16

Immunotherapy for HPV Malignancies

Lee, M. Y., & Allen, C. T. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.02.008 · Cited by 17

Squamous Carcinoma of the Ovary

Roxburgh, P., & Glasspool, R. M. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0413-1 · Cited by 16

Marrow Infiltrating Lymphocytes

Noonan, K. A., & Borrello, I. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000159 · Cited by 16

Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition

Sultan, H., Kumai, T., Fesenkova, V. I., Fan, A. E., Wu, J., Cho, H.-I., Kobayashi, H., Harabuchi, Y., & Celis, E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0549 · Cited by 16

Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence

Uccello, M., Adeleke, S. M., Moschetta, M., Ghose, A., & Boussios, S. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-1350 · Cited by 15

Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma

Lardone, R. D., Plaisier, S. B., Navarrete, M. S., Shamonki, J. M., Jalas, J. R., Sieling, P. A., & Lee, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7361 · Cited by 15

Adoptive T-Cell Therapy for Solid Malignancies

Jafferji, M. S., & Yang, J. C.-H. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.012 · Cited by 15

Current Strategies to Enhance Anti-Tumour Immunity

Cook, K., Durrant, L. G., & Brentville, V. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020037 · Cited by 15

Modulating T-cell-based cancer immunotherapy via particulate systems

Truong, D. H., Tran, T. T. P., Nguyen, H. T., Phung, C. D., Pham, T. T., Yong, C. S., Kim, J. O., & Tran, T. H. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1474360 · Cited by 15

Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma

Han, M., Kim, J. M., Cheong, J. H., Ryu, J. I., Won, Y. D., Nam, G. H., & Kim, C. H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.851628 · Cited by 14

Analysis of the whole transcriptome from gingivo-buccal squamous cell carcinoma reveals deregulated immune landscape and suggests targets for immunotherapy

Singh, R., Sarkar, N. D., Sarkar, S., Roy, R., Chattopadhyay, E., Ray, A., Biswas, N. K., Maitra, A., & Roy, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183606 · Cited by 14

Multifunctional Nanocarriers‐Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy

Choi, B., & Kim, D. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100010 · Cited by 15

Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment

Vasaturo, A., Verdoes, M., de Vries, I. J. M., Torensma, R., & Figdor, C. G. (2014) · Immunobiology · doi:10.1016/j.imbio.2014.11.007 · Cited by 14

Understanding lymphocyte metabolism for use in cancer immunotherapy

MacPherson, S., Kilgour, M. K., & Lum, J. J. (2018) · FEBS Journal · doi:10.1111/febs.14454 · Cited by 14

Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40

Levin, N., Weinstein-Marom, H., Pato, A., Itzhaki, O., Besser, M. J., Eisenberg, G., Peretz, T., Lotem, M., & Gross, G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701725 · Cited by 14

Systemic virotherapy for multiple myeloma

Oliva, S., Gambella, M., Boccadoro, M., & Bringhen, S. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1364359 · Cited by 13

Significance of Siglec‐15 expression in colorectal cancer: association with advanced disease stage and fewer tumor‐infiltrating lymphocytes

Lu, Z., Cheng, P., Huang, F., Li, J., Wang, B., Zou, S., Zheng, Z., & Peng, C. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.303 · Cited by 13

Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?Preprint

Kissick, H. T. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033704 · Cited by 13

Current status and challenges of immunotherapy in ALK rearranged NSCLC

Qi, R., Yu, Y., Shen, M., Lv, D., & He, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1016869 · Cited by 12

Nano-chemical priming strategy to enhance TGF-β resistance and anti-tumor activity of natural killer cells

Choi, S. H., Cho, H. B., Choi, J., Kim, H. J., Jang, H. J., Cho, S., Maeng, E., Park, H., Ryu, K. S., Park, K., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.008 · Cited by 12

Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies

Bastin, D. J., Walsh, S. R., Saigh, M. A., & Wan, Y. (2016) · Biomedicines · doi:10.3390/biomedicines4030021 · Cited by 13

Preclinical Development and Clinical-Scale Manufacturing of HIV Gag-Specific, LentivirusModified CD4 T Cells for HIV Functional Cure

Li, H., Lahusen, T. J., Xiao, L., Muvarak, N. E., Blažková, J., Chun, T., & Pauza, C. D. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.024 · Cited by 12

SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy

Benard, E., Casey, N. P., Inderberg, E. M., & Wälchli, S. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12917 · Cited by 12

Hematopoietic lineage-converted T cells carrying tumor-associated antigen-recognizing TCRs effectively kill tumor cells

Hu, F., Huang, D., Luo, Y., Zhou, P., Lv, C., Wang, K., Weng, Q., Liu, X., Guan, Y., Geng, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000498 · Cited by 12

Adoptive Cell Therapy for Metastatic Melanoma

Merhavi-Shoham, E., Itzhaki, O., Markel, G., Schachter, J., & Besser, M. J. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000240 · Cited by 62

Adoptive T-Cell Therapy for Cancer

Yang, J. C.-H., & Rosenberg, S. A. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 208

Adoptive T-cell Transfer in Melanoma

Itzhaki, O., Levy, D., Zikich, D., Treves, A. J., Markel, G., Schachter, J., & Besser, M. J. (2012) · Immunotherapy · doi:10.2217/imt.12.143 · Cited by 24

Adoptive Cell Transfer for Patients with Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy

Phan, G. Q., & Rosenberg, S. A. (2013) · Cancer Control · doi:10.1177/107327481302000406 · Cited by 107

Abstract IA19: Curative potential of T-cell immunotherapy for cancer

Rosenberg, S. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6074.tumimm14-ia19